Skip to Main content Skip to Navigation
Journal articles

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI

Abstract : The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.
Complete list of metadatas

Cited literature [14 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02440743
Contributor : Agnès Quemener <>
Submitted on : Wednesday, January 15, 2020 - 12:53:42 PM
Last modification on : Friday, June 19, 2020 - 3:08:56 AM
Document(s) archivé(s) le : Thursday, April 16, 2020 - 2:44:11 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Marie Vincent, Agnès Quéméner, Yannick Jacques. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. OncoImmunology, Taylor & Francis, 2013, ⟨10.4161/onci.26441⟩. ⟨inserm-02440743⟩

Share

Metrics

Record views

62